Phase 2 proof-of-concept RCT in 34 adults with Sjögren's disease (31 analysed): CRESS response at week 24 was 45.5% with efgartigimod vs 11.1% with placebo; no formal hypothesis tested. Adverse events 87.0% vs 63.6%, all grade 1-2.
RCTn = 34
Peene et al. Efgartigimod in Sjögren's disease: a phase 2, randomised, placebo-controlled, parallel-group, double-blinded, proof-of-concept study (RHO)